---
figid: PMC7372973__TJG-30-Supp4-S913-g03
figtitle: JAK-STAT signaling pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7372973
filename: TJG-30-Supp4-S913-g03.jpg
figlink: pmc/articles/PMC7372973/figure/f3-tjg-30-supp4-s913/
number: F3
caption: The JAK-STAT signaling pathway. JAK inhibitors are new therapeutic agents
  which are currently being investigated in clinical trials in IBD. First-generation
  JAK inhibitors (e.g., tofacitinib) target multiple JAKs, whereas second-generation
  JAK inhibitors (e.g., filgotinib) selectively target one JAK ().
papertitle: 2019 Expert opinion on biological treatment use in inflammatory bowel
  disease management.
reftext: Murat Törüner, et al. Turk J Gastroenterol. 2019 Nov;30(Suppl 4):S913-S944.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9598992
figid_alias: PMC7372973__F3
figtype: Figure
redirect_from: /figures/PMC7372973__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7372973__TJG-30-Supp4-S913-g03.html
  '@type': Dataset
  description: The JAK-STAT signaling pathway. JAK inhibitors are new therapeutic
    agents which are currently being investigated in clinical trials in IBD. First-generation
    JAK inhibitors (e.g., tofacitinib) target multiple JAKs, whereas second-generation
    JAK inhibitors (e.g., filgotinib) selectively target one JAK ().
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL12A
  - IL12B
  - IFNG
  - IL2
  - IL6
  - IL13
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - STAT1
  - STAT5A
  - STAT5B
  - STAT3
  - STAT4
  - Tofacitinib
  - GSK2586184
  - JNJ-54781532
  - Filgotinib
  - AVT
---
